Home > Insider Trading > Filing (0000899243-15-008442)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1631574	Wave Life Sciences Ltd.	WVE	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1657769	Partnership Limited Investment Sousei Shinsangyo Kagoshima	6-1-20, Nanei, Kagoshima City Kagoshima M0 891-0122		No	No	Yes	No
1657771	Masaharu Tanaka	C/O Kagoshima Shinsangyo Sousei Invest. Ltd. P., 6-1-20, Nanei, Kagoshima City Kagoshima M0 891-0122		Yes	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Ordinary Shares	Acquisiton	2015-11-16	161,663	$0.00	3,152,440	No	4	C	Indirect	See Footnote
Ordinary Shares	Acquisiton	2015-11-16	76,250	$16.00	3,228,690	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Ordinary Shares	Series B Preferred Shares	Acquisiton	2015-08-14	161,663	$12.37	161,663	$0.00
Ordinary Shares	Series B Preferred Shares	Disposition	2015-11-16	161,663	$0.00	161,663	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
161,663			No	4	P	Indirect
0			No	4	C	Indirect

Footnotes

The Series B Preferred Shares converted into Ordinary Shares on a one-for-one basis upon the closing of the Issuer's initial public offering of its Ordinary Shares and had no expiration date.
Shares held by Kagoshima Shinsangyo Sousei Investment Limited Partnership ("KSS"). Masaharu Tanaka, a director of the Issuer, is the representative director of Kagoshima Development Co., Ltd., the general partner of KSS and may be deemed to beneficially own the reported securities. Pursuant to Rule 16a-1 under the Securities Exchange Act of 1934, as amended (the "Act"), Mr. Tanaka disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. The filing of this Form 4 shall not be construed as an admission that Mr. Tanaka is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of the reported securities.
Share amounts reflect a 4.0415917-for-1 forward split of the Issuer's shares on November 1, 2015. The securities were purchased for $12.37 per share on a post-split basis.